Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.
An emerging body of evidence has been involved in plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though the findings are not always consistent. Our systematic epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and […]